Lexeo Therapeutics (LXEO) Income towards Parent Company (2022 - 2026)

Lexeo Therapeutics (LXEO) has 5 years of Income towards Parent Company data on file, last reported at -$20.2 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company rose 38.16% year-over-year to -$20.2 million; the trailing twelve-month figure through Mar 2026 stood at -$88.0 million (up 19.47% YoY), and the FY2025 full-year result was -$222.1 million, down 125.83% from the prior year.
• Income towards Parent Company advanced to -$20.2 million in Q1 2026, from -$21.4 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$13.4 million in Q2 2023 to a low of -$32.7 million in Q1 2025.
• A 5-year average of -$21.1 million and a median of -$20.3 million in 2025 frame the typical range for Income towards Parent Company.
• Across the five-year window, Income towards Parent Company tumbled 82.73% in 2024 and jumped 38.16% in 2026, its largest moves.
• Tracing LXEO's Income towards Parent Company over 5 years: stood at -$14.6 million in 2022, then climbed by 2.68% to -$14.2 million in 2023, then slumped by 82.73% to -$25.9 million in 2024, then advanced by 17.28% to -$21.4 million in 2025, then advanced by 5.82% to -$20.2 million in 2026.
• Business Quant data shows LXEO's Income towards Parent Company at -$20.2 million in Q1 2026, -$21.4 million in Q4 2025, and -$20.3 million in Q3 2025.